Fig_3.tif (356.92 kB)
C-index for prediction of accelerated renal function decline (eGFR decline <-3 or >-3 mL/min/1.73m2/year) for a) established risk markers (reference model: baseline UACR, current vs. never smoker, sex, systolic and diastolic blood pressure, use of oral diabetic medication, and baseline eGFR) (C-index = 0.835), b) 3-biomarker model (MMP7, TEK, and TNFR1 on top of reference model) (C-index = 0.835; p = 0.262 compared to reference model), and c) Optimal model (baseline UACR, MMP7, current vs. never smoker, sex, TEK, MMP2, systolic blood pressure, baseline eGFR, TNFR1, NPHS2, CTGF, use of oral diabetic medication, YKL-40, MMP1, MMP13, MMP8, SOST, CCL2, and NT-proCNP) (C-index = 0.896; p = 0.008 compared to reference model).
figure
posted on 2015-05-14, 04:11 authored by Michelle J. Pena, Andreas Heinzel, Georg Heinze, Alaa Alkhalaf, Stephan J. L. Bakker, Tri Q. Nguyen, Roel Goldschmeding, Henk J. G. Bilo, Paul Perco, Bernd Mayer, Dick de Zeeuw, Hiddo J. Lambers HeerspinkC-index for prediction of accelerated renal function decline (eGFR decline <-3 or >-3 mL/min/1.73m2/year) for a) established risk markers (reference model: baseline UACR, current vs. never smoker, sex, systolic and diastolic blood pressure, use of oral diabetic medication, and baseline eGFR) (C-index = 0.835), b) 3-biomarker model (MMP7, TEK, and TNFR1 on top of reference model) (C-index = 0.835; p = 0.262 compared to reference model), and c) Optimal model (baseline UACR, MMP7, current vs. never smoker, sex, TEK, MMP2, systolic blood pressure, baseline eGFR, TNFR1, NPHS2, CTGF, use of oral diabetic medication, YKL-40, MMP1, MMP13, MMP8, SOST, CCL2, and NT-proCNP) (C-index = 0.896; p = 0.008 compared to reference model).
